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Background 
Pancreatic cancer (PC) has one of the highest mortality rates of all 
cancers [1,2]. By 2030, PC will be the second most common cancer-
related death after lung cancer [3], and today PC is the third leading 
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Abstract
Background: The overall survival of patients with pancreatic cancer (PC) is dismal and has improved only slightly 
during the last decades. Early detection of PC is difficult, and less than 25% of all patients with PC are eligible for surgery. 
No validated biomarkers exist that identify PC at an early stage and predict treatment outcomes in the individual patient. 
The objective of the present study is to find diagnostic, prognostic and predictive biomarkers that can be used (1) to 
diagnose PC with high specificity and sensitivity early in the course of the disease, (2) to improve prognostication, and/or 
(3) to predict and monitor treatment effectiveness and tolerability for the individual patient.
Methods and analysis: Observational and translational open cohort study with prospective collection of biological 
materials and clinical data during all stages of the routine care of patients with PC and including patients with suspected 
pancreatic malignancy disproved after surgery. Blood samples are collected sequentially during the course of a patient’s 
treatment: before surgery, at start of adjuvant or palliative chemotherapy as well as during treatment until disease 
progression. The patients are followed until death. Demographics, disease characteristics, comorbidities and lifestyle 
factors are registered at inclusion and weight and performance status in association with each treatment cycle. Routine 
blood tests (i.e., haematology, creatinine, liver enzymes, bilirubin, carbohydrate antigen 19-9, C-reactive protein) are 
collected at regular intervals, and type of operation, chemotherapy and number of cycles given, date of disease recurrence 
in patients subjected to surgery, date of disease progression for each line of chemotherapy and date of death are recorded. 
Currently in July 7, 2019 a total of 5156 samples from 2141 patients have been collected. 
Discussion: Biomarker analyses include a range of molecules such as deoxyribonucleic acid (DNA), single nucleotide 
polymorphism (SNPs), ribonucleic acid (RNA), microRNA, proteins and metabolites. Data will be analysed using appropriate 
methods and statistical analyses.
Conclusion: It is our hope that this ongoing study will provide new information on biomarkers and will contribute to 
precise treatment options for patients with PC in order to improve outcomes.
Trial Registration: ClinicalTrials.gov ID: NCT03311776. The trial was registered retrospectively; registration date 
10/06/2017. 
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cause of cancer death, surpassing breast cancer. The incidence of PC 
increases with age, and half of the patients are older than 65 years at 
time of diagnosis [4,5]. Worldwide 458,918 people were registered with 
PC in 2018 [1]. An estimated 56,770 new cases of PC will be diagnosed 
in the United States in 2019 [2], and 45,750 patients will die [2]. In 
Denmark, there were 957 new cases of PC and 982 deaths in 2016 [6]. 
The most common type of PC is ductal adenocarcinoma (90–95%) 
[4,5], characterised by disperse tumour cells in a dense desmoplastic 
stroma [4,5], resulting in a hypoxic and avascular environment. 
Inflammation is one of the hallmarks of cancer [7-9] and contributes 
to PC initiation, promotes cell survival, inhibits apoptosis, induces 
epithelial-mesenchymal transition (EMT), and plays an important role 
in chemoresistance and enhanced invasiveness and metastasis of PC 
[10-12].  
The prognosis of many cancer patients has significantly improved 
during the last decade, whereas the prognosis of patients with PC is still 
dismal, and only 8–9% of the all patients are alive after 5 years [4,5]. 
Due to the aggressive tumour biology and paucity of clinical signs, the 
patient often presents with locally advanced or metastatic PC. Thus, 
only 15–20% of patients are suitable for surgical resection [4,5], which 
is the only curative treatment of PC. However, the majority of patients 
relapse within 2 years after pancreatic resection followed by adjuvant 
treatment with gemcitabine either in combination with capecitabine 
or nab-paclitaxel or as monotherapy [13-15]. Adjuvant treatment with 
modified FOLFIRINOX (5-fluorouracil [5-FU], leucovorin, irinotecan, 
oxaliplatin) for patients having performance status ≤1, results in the 
longest overall survival yet reported after resection, with 63% being alive 
after three years [16]. In patients with locally advanced or metastatic 
disease, chemotherapy is the only treatment option to palliate symptoms 
and prolong life. Only a few types of chemotherapy have clinical effect: 
monotherapy with gemcitabine, FOLFIRINOX and nab-paclitaxel 
in combination with gemcitabine [4,5,17,18]. Unfortunately, current 
treatments have moderate or no effect in many patients, and only 20% 
of the patients with locally advanced or metastatic PC are alive after 
1 year, and the 5-year survival is only 4–7% [13]. Furthermore, it is 
a clinical challenge to identify older patients who will benefit from 
combination chemotherapy [19].     
Although the aetiology of PC is not fully elucidated, several non-
genetic risk factors including older age, smoking, high body mass 
index (BMI), heavy alcohol use, chronic pancreatitis, inflammatory 
bowel disease and long-standing diabetes mellitus are associated with 
PC [4,5]. It has recently been concluded that chronic stimulation and 
proliferation of the pancreatic duct gland compartment in response to 
islet inflammation in type 2 diabetes mellitus (T2DM) are potentially 
novel mechanisms that serve as a link to the increased risk of 
pancreatitis in T2DM [20]. About 5 to 10% of PC occurs due to genetic 
predisposition [21]. Furthermore, pancreatic intraepithelial neoplasia 
in association with intraductal papillary mucinous and mucinous cystic 
neoplasms is a putative histologic precursor of PC [22].
In 1998, the National Institutes of Health Biomarker Definitions 
Working Group defined a biomarker as “a characteristic that is 
objectively measured and evaluated as an indicator of normal biological 
processes, pathogenic processes, or pharmacological responses to 
a therapeutic intervention” [23]. Biomarkers are divided into three 
categories: diagnostic biomarkers (ideally, diagnostic biomarker should 
establish the correct diagnosis with high sensitivity and specificity) 
which may be used for early diagnosis of a given disease [23-24]; 
prognostic biomarkers which correlate with specific clinical outcomes 
and thus progression of disease regardless of any treatment [23-25]; and 
predictive biomarkers which may be used to predict whether a given 
patient may benefit from a given treatment [23-26]. Hence, biomarkers 
may be promising tools to personalise the treatment of patients 
with PC. Potential biomarkers include a wide spectrum of genes, 
deoxyribonucleic acid (DNA), messenger ribonucleic acid (mRNAs), 
microRNAs, proteins and metabolites [27-29]. Genetic variation can be 
caused by single nucleotide polymorphism (SNPs) and copy number 
variations (CNVs), among which, the SNP is the most common type of 
genetic variation. In patients with PC, these biomarkers may be related 
to the disease itself, the associated inflammation or treatment-related 
pharmacokinetics. Biomarkers can be detected in peripheral blood, 
circulating cells or cell-free DNA in plasma [30,31], or in cancer tissue. 
Biomarkers in blood have the potential of being a more feasible, specific 
and reproducible tool for both diagnostic and prognostic purposes and 
for the monitoring of treatment and disease progression. 
Currently, the concentration of Carbohydrate antigen (CA) 19-9 in 
serum is the most widely used biomarker for assessing disease burden 
and monitoring disease recurrence and prognosis of patients with PC 
[32]. However, CA 19-9 is not a specific biomarker for PC. Elevated 
CA 19-9 is also seen in pancreatitis, obstructive jaundice, cirrhosis and 
other gastrointestinal cancer. Moreover, CA 19-9 is not expressed in 
patients who lack Lewis antigen [33]. 
In line with increasing demand for precision medicine, the need to 
bridge patients and high-quality clinical data to molecular and genetic 
research is self-evident. New biomarkers for early diagnosis, prediction 
of treatment effects and better evaluation of prognosis and monitoring 
of patients with PC, including older (> 70 years) patients and patients 
with risk factors for PC, among others diabetes mellitus, pancreatitis, 
pancreatic intraepithelial neoplasia as well as genetic predisposition, 
are urgently needed to reduce mortality from PC. The focuses of our 
study, the BIOPAC “Biomarkers in patients with Pancreatic Cancer” 
study, are the identification of a panel of biomarkers in blood and tissue 
for early detection of PC, selection of patients who may benefit from 
neoadjuvant chemotherapy, prognostication and prediction of effect of 
different types of systemic therapies. Furthermore, the role of genetic 
factors and lifestyle in PC will be investigated. The present protocol is 
an observational, prospective, translational research study of patients 
with PC included in the nationwide Danish BIOPAC Biobank. It will 
include many translational biomarker studies of gene profiles, DNA, 
RNAs, microRNAs, SNPs, proteins and metabolites in patients of all 
ages and stages of PC. We will test the following hypothesis: “New 
circulating biomarkers and tissue biomarkers from patients with PC, 
including older patients and patients with comorbidity (e.g. T2DM), 
are useful for early diagnosis and valuable for better prediction of 
prognosis and selection of treatment”.
This protocol has been prepared and implemented according 
to the REMARK guidelines [34,35]. To increase awareness of the 
BIOPAC study and facilitate dissemination of methods to the scientific 
community, the standard operating procedures used, current progress 
as well as completed and ongoing studies, are constantly updated on the 
BIOPAC Biobank website (www.herlevhospital.dk/BIOPAC). In this 
paper, we describe the study design and specify methods for sample 
collection, processing and archiving of data in the BIOPAC Biobank.
Objectives
The translational goal of the BIOPAC study is to improve outcomes 
and quality of life for patients with PC by improving personalised 
cancer treatment. The aims are to:
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• identify patients with PC at an early stage and thereby increase 
the number of patients who can be radically resected.
• predict treatment response and prognosis of patients with PC 
to optimise treatment selection, i.e. to select patients who will 
benefit or not benefit from different types of therapy.
• identify tumour progression before computed tomography 
(CT) scans during treatment and follow-up to save patients 
with PC from unnecessary toxic therapies which are ineffective 
and compromise quality of life.
• include real-life, unselected patients including older patients 
(>70 years) and patients with comorbidities such as T2DM.
Materials and Methods 
Study design and setting 
In July 2008, the Danish BIOPAC Study “Biomarkers in patients 
with Pancreatic Cancer (BIOPAC) – can they provide new information 
of the disease and improve diagnosis and prognosis of the patients?” 
was initiated with the aim of conduction translational research. It is a 
prospective multicentre biomarker study in which biological samples 
(blood and cancer tissue), and clinical data are collected prospectively 
in Danish patients with localised, locally advanced or metastatic PC 
treated at seven oncological expert centres in Denmark as well as patients 
subjected to surgery in whom PC was suspected but not histologically 
confirmed. All patients included in the study are >18 years of age, have 
histologically verified PC or ampullary adenocarcinoma in a resected 
specimen, or histopathological confirmation of carcinoma if surgery 
has not been performed, and have signed an informed consent form. 
The patients are treated with different types of chemotherapy according 
to national guidelines www.gicancer.dk. One group consists of patients 
that have undergone surgery for PC, and a subgroup of patients consists 
of patients who have undergone surgery due to suspected PC but in 
whom no cancer was found on histologic examination after resection. 
Clinical data and outcomes are registered in the BIOPAC database, and 
biological samples are collected via the Danish nationwide BIOPAC 
biobank. Patient inclusion started in July 2008 and will continue until 
July 2028, with follow-up until July 2035. The inclusion period can be 
extended if deemed advisable after assessment by the investigators. 
The patients included in the BIOPAC study are followed from time 
of diagnosis and during treatment and follow-up until death. Relevant 
clinical characteristics of the patients are included in the BIOPAC 
database and include a large number of parameters.
The BIOPAC study is a nationwide collaboration between 
Departments of Oncology, Clinical Biochemistry and Pathology in 
Denmark. As of July 7, 2019, seven hospitals from all parts of Denmark 
(Rigshospitalet, North Denmark Regional Hospital, Copenhagen 
University Hospital in Herlev, Zealand University Hospital in Roskilde 
and Næstved, Odense University Hospital, Aalborg University 
Hospital, and Hospital Lillebaelt in Vejle) have agreed to participate in 
the BIOPAC study. The BIOPAC biobank is housed at the Copenhagen 
University Hospital in Herlev and represents the first comprehensive 
PC biobank in Denmark.
Inclusion of patients is ongoing and will continue until 5000 
patients are included. As of 7 July 2019, 5156 blood samples from 2141 
patients have been collected. The number of patients included each year 
in the BIOPAC Study is approximately 200. Different types of biological 
material, e.g. blood and cancer tissue, are collected, handled and stored 
according to nationally approved Standard Operating Procedures 
(SOPs), see section “Biological Material”. 
Participants
The BIOPAC study is an open cohort study. Patients are eligible for 
inclusion if they are in routine clinical follow-up after a diagnosis of 
PC. A subgroup of patients operated on due to suspicion but without 
evidence of PC is also included since blood samples were taken before 
surgery. Patient inclusion and follow-up are carried out by nurses and 
physicians when the patients meet for scheduled routine clinical visits. 
The numbers of potentially eligible patients for the study are shown in 
Figure 1.
Clinical data
At the time of inclusion, the following clinical data are collected in 
the BIOPAC database:
1.  Patient demographics: e.g. age, gender, diagnosis, weight and 
weight loss, height, BMI, performance status, family history of 
PC, medications, histological/cytological characteristics, TNM 
stage, site of metastasis, as well as lifestyle factors like smoking 
status and alcohol intake.
2.  Comorbidities including Charlson comorbidity index: 
e.g. other types of cancer, diabetes, hypertension and 
hypercholesterolemia.
3.  Paraclinical information: e.g. routine blood tests (haematology, 
liver enzymes, bilirubin, creatinine) including CA 19-9 and 
C-reactive protein and information on CT and/or positron 
emission tomography and computed tomography (PET/CT).
4.   Exposures: e.g. date of operation and treatment with one or 
more of the following types of chemotherapy: gemcitabine, 
nab-paclitaxel + gemcitabine, FOLFIRINOX, capecitabine + 
gemcitabine, or oxaliplatin + capecitabine. Start and stop date 
and reason for treatment withdrawal as well as number of cycles 
in each line of treatment and adverse events.
5.  Outcomes: e.g. respectability status and date of disease 
recurrence (in patients operated on), date of disease progression 
after each line of treatment and date of death. 
Any oncological, surgical and/or medical treatment undertaken, 
and the monitoring of disease status (CT, PET/CT) are done as part of 
routine care according to international and national guidelines.
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Figure 1: Inclusion of patients in the BIOPAC study per year.
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Biological samples
The collected biological materials include blood samples and 
tissue from the primary tumour and/or metastasis. Blood collection 
timepoints for patients operated on and patients with unresectable 
PC are shown in Figure 2. Blood sampling continues until patient’s 
withdrawal of the informed consent at his/her own request and until 
the study is closed or terminated.
Peripheral blood is collected in four EDTA tubes (4 x 9 ml), two 
serum tubes (2 x 9 ml) and two PAX gene blood RNA tubes (2 x 2.5 
ml, Becton &  Dickinson, Lyngby, Denmark). Samples are processed 
according to the nationally approved SOP for blood (Figure 3). 
Within 2 hours, tubes are centrifuged at 2300xg at 4˚C for 10 min. 
After centrifugation, plasma, buffy coat and serum are aliquoted into 
10 tubes with 1.5 ml plasma EDTA, 3 tubes with buffy coat (from the 
EDTA tubes) and 5 tubes with 1.5 ml serum. The 2.5 ml whole blood 
in 2 PAX gene blood RNA tubes is collected and handled according to 
the manufacturer’s instructions. PAX gene blood RNA tubes are kept at 
room temperature for 2-72 hours, then frozen at -20˚C for 24-48 hours 
and finally stored at -80˚C. Buffy coat, EDTA plasma and serum are 
stored at -80˚C.
Pre-analytical factors such as date of sampling, handling and 
storage, and the exact handling procedure are registered in the 
nationwide BIOPAC registry. Tissue samples collected at time of 
surgery are handled according to the SOP used in the nationwide Bio- 
and Genome Bank Denmark registry (http://www.cancerbiobank.dk). 
Figure 2: Schematic presentation of blood sampling strategies. Any patient followed in the BIOPAC study may participate at time of diagnosis and before surgery 
or at start of adjuvant or palliative chemotherapy.
Figure 3: Standard Operating Procedure (SOP) for blood handling in the BIOPAC study. Peripheral blood is collected in four EDTA tubes (each with 9 ml blood), two 
serum gel tubes (each with 9 ml blood) and two PAXgene blood RNA tubes (each with 2.5 ml blood). Serum tubes coagulate at room temperature for 30 min to 2 
hours. EDTA and serum tubes are centrifuged at 2300 × g at 4°C for 10 min. EDTA plasma (10 × 1.5 ml) and serum (5 × 1.5 ml) are isolated. From the EDTA tubes, 
buffy coat is isolated after removal of EDTA plasma (in three tubes). Plasma and serum samples are stored at ≤ -80°C. PAXgene blood RNA tubes are kept at room 
temperature for 2–72 hours, then frozen at -20°C for 24–48 hours and stored at -80°C.
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Assay methods
The BIOPAC study aims to investigate the following biomarkers in 
blood and tissue: 
1) Genetic variation using next generation sequencing (NGS) and 
whole genome sequencing (WGS), Kirsten rat sarcoma viral 
oncogene homolog (KRAS) mutations, specific mutations, and 
RNA and microRNA expression profiles.
2) Protein biomarker profiles of cancer, angiogenesis and 
inflammation using enzyme-linked immunosorbent assay 
(ELISA) and the Proseek Multiplex protein arrays (panels of 
92 proteins) (Olink Proteomics, Uppsala, Sweden, www.olink.
com), or proteomics platforms, such as mass spectrometry, 
protein-array or multiplexed ELISA.
3) Cell-free DNA in plasma or serum. 
4) Metabolites using nuclear magnetic resonance spectroscopy.
All samples will be analysed in pseudo or anonymised form to 
ensure blinded testing by the laboratory personnel. 
The list of specific diagnostic, prognostic and predictive biomarkers 
will be updated continuously according to new discoveries. The 
methods of biomarker analysis are rapidly expanding and improving; 
the best method will be used at time of analysis.
Statistical methods
For the longitudinal samples, it is expected that the numbers 
collected during a 20-year period will provide sufficient statistical 
power to identify diagnostic, prognostic and predictive biomarkers. 
Knowledge within the field is still insufficient; thus, it is not possible 
to perform a comprehensive power calculation. This will, however, be 
performed before any biomarker analysis is done. 
In general, statistical analyses are carried out according to available 
data. Comparison of group demographics will be performed with 
Student’s t-test, Pearson’s chi-square test or Mann-Whitney U-test 
according to the distribution of data. Treatment duration and time to 
event will be explored with Kaplan-Meier curves, log-rank statistics 
and Cox regression analyses. Treatment outcomes across groups or 
according to specific biomarkers are analysed with logistic regression 
analyses. Multivariable analyses will be performed to study the impact 
of potential confounders. These confounders may be identified in 
the BIOPAC registry (gender, age, smoking status, or other baseline 
characteristics). 
All included patients are recruited and treated in routine care 
across Denmark, and this will inevitably lead to missing data (missing 
sampling of biological material, missing registration of corresponding 
clinical data whenever biological material is collected). However, due 
to the unique Danish Central Personal Registry (CPR) there will be 
a 100% follow-up regarding date of death and patients are only lost 
to follow-up if they emigrate from Denmark. For sensitivity, various 
statistical methods may be applied to test the robustness of the results. 
Statisticians are involved if necessary.
Ethics and Dissemination
The BIOPAC study protocol has been approved by the Danish Ethics 
Committee (VEK, j.nr. KA-20060113) and the Danish Data Protection 
Agency (j.nr. 2012-58-0004; HGH-2015-027; I-Suite j.nr. 03960). All 
patients receive verbal and written information before enrolment 
and give written consent at baseline according to the guidelines of 
the Danish Ethics Committee. All patients are informed that they can 
withdraw from the study at any time without any consequences for 
their treatment. If a patient withdraws, all blood and tissue samples 
are discarded, and all patient-related information is deleted from the 
BIOPAC study. 
The sampled volume of blood for the study is 59ml per patient visit 
and a maximum of 767 ml per year. The sampling of blood for the study 
is performed simultaneously with scheduled routine blood sampling, 
thus minimising the discomfort for the patient. Tissue samples are 
collected at time of operation and at time of diagnosis (core needle and/
or fine-needle aspiration biopsies from metastases or primary tumour) 
in patients with locally advanced or metastatic PC. 
The results of the studies are expected to be valid on a group level 
but not on an individual level, and the individual patient is, therefore, 
not expected to benefit from knowledge of individual measurements. 
Patients will be given the option to be contacted with information about 
overall study results and whether these have any significance for them. 
Direct feedback to the patient may be relevant if mutations in known 
disease-linked genes are discovered, and it will be provided according 
to the guidelines directed by the Danish Ethics Committee (document 
no. 1293688, October 2013). The physician in charge of the project at 
each participating department is responsible for conducting the study 
in accordance with the Helsinki declaration. Study participation does 
not affect the treatment course of individual patients, and the patients 
will be treated according to normal clinical practice. 
Due to the large number of patients included in the study, it will 
be possible to perform exploratory/discovery biomarker studies as 
well as validation biomarker studies. All biomarkers will be evaluated 
and published according to the REMARK [34,35] guidelines. Results 
will be published in international peer-reviewed scientific journals 
and presented at international conferences. Negative, positive as well 
as inconclusive results will be published. If relevant, collaboration 
with international researchers will be established to facilitate the right 
expertise for biomarker analyses. Several biomarker studies that include 
patients from the BIOPAC study have already been published [36-46] 
and others are in preparation.
Study Status
Recruitment started 3 July 2008 and is expected to continue until 1 
July 2028, with follow-up until 2 July 2035. Currently (7 July 2019) 2141 
patients (out of planned 5000) have been enrolled in the study and 5156 
blood samples have been collected.
Strengths and limitations of this study
• Nation-wide collection of biological materials and 
corresponding extensive clinical data provide the opportunity to 
discover and/or validate a wide range of diagnostic, prognostic 
and predictive biomarkers in patients with suspected or 
confirmed PC.
• Recruitment of patients with PC treated in routine care is 
expected to provide valuable data on “real-life patients” (e.g. 
older patients with comorbidities), which are different from 
the more homogeneous patient population in randomised 
controlled trials.
• Standardised collection of samples and quality control ensure 
comparability between samples from different departments and 
enable research in a large group of patients.
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• Limitations may be encountered regarding patient recruitment 
and in the collection of clinical and biological data in patients 
with PC during follow-up in routine care and across several 
types of treatment.
• The non-randomised study design inherits the risk of 
confounding, and thorough statistical analysis and confounder 
adjustment are therefore important.
Discussion
In this observational, prospective, translational research, biomarker 
study of patients with PC, blood and tissue samples are collected 
in routine care. Each blood and tissue sample are closely linked to 
extensive clinical data regarding PC, medical treatment, treatment 
efficacy, adverse events and comorbidities. The BIOPAC study protocol 
allows for a large-scale collection of blood and tissue samples with 
the aim to identify new biomarkers that can be used for improved 
personalised treatment of patients with PC.
Apart from serum CA 19-9, no biomarkers are used in routine 
evaluation of patients with PC, and serum CA 19-9 is non-specific as a 
diagnostic, predictive or prognostic marker.
Due to the generally poor outcome in these patients, it would be 
useful to identify clinical predictors to avoid over-treatment. The 
identification of patients with resettable tumours on imaging modalities 
but with micro-metastases would also be of great clinical value. These 
patients should be treated with chemotherapy upfront without the 
waste of time and potential harm associated with unnecessary surgery. 
In some cases, patients are exposed to explorative surgery without 
confirmation of cancer; thus, differentiation between benign pancreatic 
conditions and PC is another but no less important issue.
Future treatments stress the importance of an improved ability to 
select the most effective treatment in the individual patient with PC. 
Development of diagnostic, prognostic and predictive biomarkers is 
expected to facilitate personalised medicine in the future.
Since it is mandatory in Denmark to register all newly diagnosed 
cases of cancer (Danish Cancer Registry) as well as patients diagnosed 
with PC (Danish Pancreatic Cancer Database (DPCD)) [47], we can 
estimate that the completeness of inclusion of patients in the BIOPAC 
study is ≈20%. One of the reasons for this low degree of coverage is 
that some patients are not referred to oncological or surgical treatments 
due to their poor performance status. In addition, implementation of 
new IT systems (EPIC) or local reorganisation in the hospitals involved 
clearly affects BIOPAC enrolment. Two oncological departments (out 
of nine departments in Denmark treating patients with PC) did not 
have the capacity to participate in the BIOPAC study. 
Since patients are recruited across several types of treatment, patient 
inclusion may take some time in order to obtain enough samples for a 
specific research question. The non-randomised study design inherits 
the risks of confounding. On the other hand, the wide recruitment of 
patients treated in routine care may provide valuable data in a broad 
spectrum of patients such as older patients with comorbidities and 
patients with T2DM. This may be a supplement to data generated in 
randomised trials. 
Hopefully, the BIOPAC study will lead to biomarkers that improve 
our ability to diagnose PC more accurately and at an earlier stage, 
improve prognostication of patients with PC, and predict treatment 
effectiveness in the individual patient (tailored treatment).
Conclusion
The BIOPAC study is the first comprehensive study with prospective 
collection of biological materials and clinical data for researchers and 
clinicians wishing to conduct basic, clinical and translational research 
in PC in and outside Denmark. Since its initiation, the BIOPAC study 
has undertaken several projects in a multidisciplinary setting and 
constantly promotes the advance of translational research and precision 
medicine within the PC landscape.
Researchers who are interested in collaboration regarding samples 
and/or clinical data from the BIOPAC study should contact the BIOPAC 
team.
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